William R. Brody, Chairman of the Board
M.D. and Ph.D. Stanford University
President, The Salk Institute (2009-2015) and President, The Johns Hopkins University (1996-2009)
>100 publications and 2 U.S. patents in the fields of medical imaging, medical acoustics, computed tomography, digital radiography, and magnetic resonance imaging
Dr. Brody’s achievements in biomedical engineering have led to his recognition by numerous national and international organizations. He is a member of the Institute of Medicine and the National Academy of Engineering and a fellow of the Institute of Electrical and Electronic Engineers, the American College of Radiology, the American College of Cardiology, the American Heart Association, the International Society of Magnetic Resonance in Medicine, the American Institute of Biomedical Engineering, and the American Academy of Arts and Sciences. In 2010, he was awarded the Gold Medal of the Radiological Society of North America for his contributions to medical imaging science. He is a national figure in efforts to encourage innovation and strengthen the U.S. economy through investments in basic research and education. Most recently, he has written and spoken extensively to promote a fuller discussion of health care reform.
Hong Cai, Co-Founder & Chief Executive Officer
Ph.D. University of Southern California (1995)
Staff Scientist, Los Alamos National Lab, (1995-2009)
Over 20 years of experience in molecular bioassay development
Dr. Cai has more than 20 years of experience in the field of molecular biology and is the inventor of the technology used in Mesa Biotech’s point-of-use nucleic acid-based diagnostic platform. As the CEO/President, she manages business operations with a primary focus on transitioning R&D efforts into product development. Prior to establishing Mesa Biotech, Dr. Cai spent 13 years as a principal investigator at Los Alamos National Laboratory, managing and leading projects (totaling more than $10 million) focused on the development of nucleic acid-based assays for forensic analysis, biothreat pathogen detection, and human disease diagnosis, including single nucleotide polymorphism-based genotyping, single fragment sizing-based DNA forensic analysis, and a variety of PCR, RT-PCR and isothermal amplification-based nucleic acid tests for human disease diagnosis.
R. Bruce Cary, Co-Founder & Chief Scientific Officer
Ph.D. University of Colorado, Boulder (1994)
Staff Scientist, Los Alamos National Lab (1995-2009)
Over 20 years of nucleic acid array and assay development
Dr. Cary is the inventor of the lateral flow microarray and the passive buffer exchange nucleic acid purification technologies that are the basis for the Mesa Biotech’s point-of-use molecular diagnostic platform. As CSO, he leads projects for the development of rapid molecular tests and diagnostics for infectious disease, food safety, agricultural and human pathogens. Prior to co-founding Mesa Biotech, he spent 13 years as a principal investigator and scientist at Los Alamos National Laboratory, leading projects focused on biodefense, pathogen detection, nucleic acid metabolism and microarray gene expression technology.
Eric Sagerman, Member of the Board of Directors
MBA Amos Tuck School, Dartmouth College
Former CEO Universata, Head of Strategic Marketing for Allianz Global Investors, SVP American Express, Board Member of Salk Institute
>20 years experience as an accomplished global executive with a proven record of growing and restructuring businesses through innovation